This website uses cookies to improve performance and your user experience on our website. If you do not agree with the use of cookies other than the essential ones, you can manage your preferences by clicking on "Cookie Settings"
It's always nice to get a little recognition. We are thus delighted to share that BMA and its partners, Filipe Baptista, Paulo Monteverde and Petra Fernandes, were ranked Gold Tier by IAM Patent 1000, 2024 edition.
"A force to be reckoned with in patent litigation, BMA has an outstanding track record and many benchmark wins to its name. Its lawyers are highly adept when it comes to advocacy and negotiation and are commercially aware, showing a keen sense as to where business risk lies. The leading practitioners are Filipe Baptista, Paulo Monteverde and Petra Fernandes, who regularly team up to give prestigious clients the best chance of success. Baptista and Monteverde are influential voices in the Portuguese and international IP community and carry gravitas into the courtroom. Fernandes has become a go-to for pharmaceutical companies in need of decisive representation in litigation and advice on regulatory law."
It's always nice to get a little recognition. We are thus delighted to share that BMA and its partners, Filipe Baptista, Paulo Monteverde and Petra Fernandes, were ranked Gold Tier by IAM Patent 1000, 2024 edition.
"A force to be reckoned with in patent litigation, BMA has an outstanding track record and many benchmark wins to its name. Its lawyers are highly adept when it comes to advocacy and negotiation and are commercially aware, showing a keen sense as to where business risk lies. The leading practitioners are Filipe Baptista, Paulo Monteverde and Petra Fernandes, who regularly team up to give prestigious clients the best chance of success. Baptista and Monteverde are influential voices in the Portuguese and international IP community and carry gravitas into the courtroom. Fernandes has become a go-to for pharmaceutical companies in need of decisive representation in litigation and advice on regulatory law."